stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) Debt to equity
Trulieve Cannabis Corp.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.3× from fiscal 2025 (0.3×). Over the past ten years it has ranged from 0.2× (fiscal 2021) to 0.4× (fiscal 2024); the current reading is higher than 40% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 0.0× and in line with the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.3× | (41.45%) |
| FY2024 | 0.4× | 13.55% |
| FY2023 | 0.4× | 4.83% |
| FY2022 | 0.4× | 47.07% |
| FY2021 | 0.2× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.5× | 43.75% |
| Mar 2026 | 0.3× | 22.81% |
| Dec 2025 | 0.3× | (43.84%) |
| 16 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| ALVO Alvotech compare | −6.8× |
| PBH Prestige Consumer Healthcare Inc. compare | 0.0× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 0.0× |
| RGC Regencell Bioscience Holdings Limited compare | 0.0× |
| TRLV Trulieve Cannabis Corp. | 0.0× |
| ANIP ANI Pharmaceuticals, Inc. compare | 0.0× |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.1× |
| PRGO Perrigo Company plc compare | 1.3× |
| XERS Xeris Biopharma Holdings, Inc. compare | 3.9× |
| Drug Manufacturers Specialty & Generic industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on TRLV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement